Caribou Biosciences appoints Nancy Whiting to board of directors

Caribou Biosciences, Inc.

Nancy Whiting, Pharm.D., appointed as Class II director effective August 24, 2021.
She receives $40,000 annual cash retainer plus $5,000 for compensation committee service.
Dr. Whiting brings over 17 years of biotech experience, most recently as EVP at Seagen Inc.
Her oncology drug development expertise aligns with Caribou's pipeline of allogeneic cell therapies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nancy C. Whiting

Director

CRBU · Caribou Biosciences, Inc.

Effective: 2021-08-24
Filed: August 25, 2021, 7:59 PM ET

unanimously agreed to extend an offer to Nancy C. Whiting, Pharm. D. to serve as a Class II director of the Company, which offer Dr. Whiting accepted on August 24, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy C. Whiting was appointed as Director at Caribou Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

unanimously agreed to extend an offer to Nancy C. Whiting, Pharm. D. to serve as a Class II director of the Company, which offer Dr. Whiting accepted on August 24, 2021.

View on SEC.gov

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-001559

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.